FDA authorizes marketing of Medasense’s NOL® (nociception level index) technology through a De Novo grant
March 8, 2023
FDA authorizes marketing of Medasense’s NOL® (nociception level index) technology through a De Novo grant
Medasense Biometrics Ltd. announced today that the U.S. Food and Drug Administration (FDA) has granted…